Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

NCT03473925 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Non-small Cell Lung Cancer
Castration Resistant Prostate Cancer
Microsatellite Stable Colorectal Cancer

Interventions

DRUG: Navarixin
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC